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Abstract
ADP-ribosylation factor 1 (Arf1) plays a critical role in regulating secretory traffic and membrane
transport within the Golgi of eukaryotic cells. Arf1 is activated by guanine nucleotide exchange
factors (ArfGEFs) which confer spatial and temporal specificity to vesicular transport. We
describe here the discovery and characterization of Golgicide A (GCA), a potent, highly specific,
and reversible inhibitor of the cis-Golgi ArfGEF, GBF1. Inhibition of GBF1 function resulted in
rapid dissociation of COPI vesicle coat from Golgi membranes and subsequent disassembly of the
Golgi and trans-Golgi network (TGN). Secretion of soluble and membrane-associated proteins
was arrested at the ER-Golgi intermediate compartment, whereas endocytosis and recycling of
transferrin was unaffected by GBF1 inhibition. Internalized shiga toxin was arrested within the
endocytic compartment and was unable to reach the dispersed TGN. Collectively, these results
highlight the central role for GBF1 in coordinating bidirectional transport and maintaining
structural integrity of the Golgi.
ADP-ribosylation factor proteins, or Arf proteins, are members of the Ras superfamily of
small guanosine triphosphatases (GTPases) and mediate vesicular transport in the secretory
and endocytic pathways. The Golgi-localized Arf1 is present in all eukaryotic cells and
regulates both anterograde and retrograde traffic1. As expected for members of the Ras
GTPase family, Arf1 cycles between its cytosolic GDP-bound form and its membrane-
associated GTP-bound form. In its GTP-bound state, Arf1 recruits adaptor and vesicle coat
proteins to initiate the formation and release of transport vesicles. More specifically, Arf1
recruits the heptameric coatomer complex at the cis-Golgi face, resulting in assembly of
COPI coated vesicles, while clathrin adaptor proteins are recruited to the trans-Golgi
network (TGN) and endosomes.
The Arf activity cycle is initiated by the interaction of Arf1 with guanine nucleotide
exchange factors (GEFs), which exchange GDP for GTP and allow for spatiotemporal
activation of Arf1. The ArfGEFS for Arf1 are divided into two families consisting of the
large brefeldin A (BFA; 1)-susceptible molecules, which localize to the Golgi and TGN, and
the smaller brefeldin A-resistant ARNO-family GEFs, which predominantly localize to
endosomes2,3. In mammalian cells, the BFA-susceptible ArfGEFs include GBF1 (Golgi
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tBFA resistance factor 1), a cis-Golgi-localized GEF that assists in the recruitment of coat
protein COPI4–6, and BIG1 and BIG2, two functionally similar TGN-localized GEFs that
facilitate recruitment of clathrin coat protein7,8. Following activation by GBF1, Arf1-
mediated COPI coat recruitment enables vesicle transport between the Golgi and
endoplasmic reticulum (ER)9. Activation by BIG1 and BIG2 results in Arf1 recruitment of
adaptor proteins (AP-1, AP-3, and AP-4), which mediate transport between endosomes and
either the TGN or lysosomes, and Golgi-associated, gamma adaptin ear containing, Arf-
binding proteins (GGA 1–3), monomeric proteins involved in trafficking from the TGN and
within the endosomal compartment 10–15.
Recently, the function of individual ArfGEFs has been explored. Among the ArfGEFs,
GBF1 has been studied most intensively, either by siRNA-mediated silencing4,16–18 or by
the expression of dominant-negative forms5,19–21. The phenotypic and functional effects of
these perturbations have not been in complete agreement but nevertheless indicate that
GBF1 is essential to intra-Golgi transport. We describe here the discovery and
characterization of a potent, highly specific, and rapidly reversible small molecule inhibitor
of GBF1 function. This compound, which we called golgicide A (GCA; 2) reveals diverse
and distinct roles for GBF1 in maintaining structure and bidirectional transport through the
Golgi and trans-Golgi network.
RESULTS
Golgicide A (GCA) is a potent and highly effective inhibitor of shiga toxin activity
From a high-throughput screen for small molecules that inhibit the effect of bacterial toxins
on host cells22, we identified a compound that potently and effectively protected Vero cells
from shiga toxin. This compound, which we subsequently named Golgicide A (GCA; Figure
1a), inhibited the effect of shiga toxin on protein synthesis with an IC50 of 3.3 μM (Figure
1b). When treated at a concentration of 10 μM, Vero cells where highly protected against
the effects of shiga toxin (Figure 1c).
GCA causes reversible dissociation and dispersal of the Golgi and TGN
Other compounds identified in this screen acted through the inhibition of intracellular toxin
transport22, leading us to examine the effect of GCA on toxin trafficking and on intracellular
organelle morphology. Immunofluoresence experiments demonstrated dramatic effects of
GCA on the Golgi and TGN. Whereas the Golgi remains as a tightly organized perinuclear
ribbon in untreated cells, GCA caused complete dispersal of the medial-Golgi markers
giantin (Figure 2a) and the cis-Golgi marker GM130 (Figure 2b). These morphological
effects on the cis- and medial-Golgi were highly reminiscent of those caused by brefeldin A
(BFA)23,24. Time-course experiments revealed that the Golgi initially became extensively
tubulated prior to its complete dispersal (Supplemental Figure 1a), similar to the effects of
BFA on cis- and medial-Golgi. Treatment with GCA resulted in a diffuse and punctate
distribution of the medial-Golgi marker giantin. The punctate structures were in contact with
Sec31-positive foci, indicative of their association with ER exit sites (ERES; Supplemental
Figure 1b). These findings were also very similar to BFA which causes Golgi matrix
proteins to concentrate at ERES 25. Effects of these compounds on the TGN, however, were
subtly different. Whereas BFA induced the formation of tubules derived from TGN and
endosomes, GCA caused the TGN to disperse into small vesicles that subsequently
disseminated throughout the cell (Figure 2c and Supplemental Figure 2).
The morphologic effects of GCA did not result from disruption of microtubules or actin
cytoskeleton (Supplemental Figure 3). Nor did GCA interfere with transit of transferrin
through the endocytic and recycling pathways (Supplemental Figures 4a and 4b). Finally,
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tthe effects of GCA were found to be rapidly reversible. Within 15 minutes of removing the
compound, the Golgi and TGN began to reassemble (Supplemental Figure 5a). The effects
of GCA on protein secretion (Supplemental Figure 5b) were likewise found to be completely
reversible within 1 hr of compound removal.
GCA disperses COPI but not AP1 or GGA3 from Golgi membranes
BFA inhibits Arf1 activation, resulting in the rapid dispersal of Golgi-associated vesicle coat
proteins COPI and AP-1 at the Golgi and TGN, respectively26–28. Since compound GCA
had similar effects on the Golgi to BFA, we compared the effects of these compounds on
COPI, AP-1 and GGA3 localization. GCA treatment, similar to BFA, resulted in a rapid
redistribution of COPI from the Golgi, which was evident within 5 minutes and occurred
prior to morphologic changes to Golgi structure and was similar to the effect of BFA (Figure
2d). In contrast, AP-1 (Figure 2e) and GGA3 (Figure 2f) remained associated with the TGN
until the Golgi and TGN began to disperse. These results were distinct from those of BFA,
which caused rapid dispersal of AP-1 and GGA3 to a diffuse cytoplasmic distribution within
minutes of BFA addition.
In summary, GCA and BFA have similar phenotypic effects on medial- and cis-Golgi which
correlate with rapid dispersal of COPI from Golgi membranes. In contrast, these two
compounds have differing morphologic effects on the TGN, and have differing effects on
AP-1 and GGA3 localization.
Phenotypic effects of GCA are similar to expression of dominant-inactive GBF1
The observation that GCA rapidly dispersed βCOP but not AP1 or GGA3 from Golgi
membranes suggested that GCA may specifically target GBF1, the ArfGEF responsible for
Arf1 activation and COPI recruitment to cis-Golgi membranes, and not affect BIG1 or
BIG2, the ArfGEFs responsible for Arf1 activation and vesicle coat recruitment at
endosomes and TGN (Figure 3a). Consistent with the possibility that GCA inhibited GBF1
activity, we found that expression of GBF1-E794K, a dominant-inactive GBF1 21, resulted
in dispersal of βCOP from Golgi membranes and disruption of TGN and medial-Golgi
structure (Figure 3b), similar to the effects of GCA. The dominant inactive GBF1 was
previously shown to localize to the ER-Golgi intermediate compartment (ERGIC) 21, and
we found that upon GCA treatment, wild-type GBF1 was largely colocalized with
ERGIC-53, a marker for this compartment (Figure 3c). Therefore, treatment with GCA
phenotypically resembled expression of dominant-inactive GBF1, further supporting the
possibility that GBF1 was the target of GCA.
We next examined the effect of BIG1 overexpression on susceptibility to BFA and GCA.
Overexpression of BIG1 was recently shown to partially rescue the effects of BFA on the
TGN 16. We confirmed that BIG1 transfection was partially protective against BFA effects
on the TGN (Supplemental Figure 6a) and had no protective effect at the Golgi
(Supplemental Figure 6b). By comparison, expression of BIG1 had no protective effect
against GCA on either the TGN or Golgi (Supplemental Figures 6a and 6b).
GBF1 is selective for GBF1
In the course of examining the effect of GCA on various cell types, we found that MDCK
cells were resistant to GCA as evidenced by a lack of effect of this compound on Golgi
morphology and βCOP localization (Supplemental Figure 7a). The Golgi apparatus of
MDCK cells has also been reported to be resistant to the effects of BFA29–31. Since BFA is
known to bind within the highly-conserved Sec7 domain of Golgi-associated ArfGEFs, and
because we suspected GBF1 to be the target of GCA, we examined the possibility that
differences in the canine GBF1 Sec7 domain accounted for MDCK cell resistance to both
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tcompounds. We amplified, cloned, and sequenced the canine GBF1 Sec7 domain. Analysis
of several independent clones revealed a leucine substitution for methionine at residue 832
of the full-length protein (numbering corresponds to the human GBF1 sequence).
Comparison with all other mammalian GBF1 homologues revealed this substitution to be
unique to the canine gene (Supplemental Figure 7b). Interestingly, mutagenesis of the
corresponding methionine to leucine in the yeast ArfGEF homologue Gea1 and the human
GBF1 resulted in resistance to BFA32,33.
The M832L substitution was introduced into the hamster GBF1 and the effect of its
expression on GCA susceptibility was examined in transfected cells. Vero cells expressing
this mutant were highly resistant to GCA, as evidenced by maintenance of βCOP
localization, TGN morphology, and cis-Golgi structure, even at compound concentrations as
high as 100 μM (Figure 4a). As described later, expression of GBF1-M832L rescued the
functional effects of GCA on secretion and on retrograde toxin transport. The ability of this
mutant to fully protect Vero cells against the phenotypic and functional effects of this
compound indicate that GCA specifically targets GBF1 and does not have evident “off-
target” effects.
The mechanism of GCA specificity for GBF1 was investigated by molecular modeling and
site-directed mutagenesis. The GBF1 Sec7 domain was modeled in complex with Arf1 using
the published structure of the Arf1-ARNO-BFA complex34. Although there is considerable
sequence divergence between GBF1 and BIG1/BIG2 (Figure 4b), the predicted tertiary
structure of the GBF1 Sec7 domain is very similar to that of ARNO (Figure 4c). When the
ARNO-Arf1 and predicted GBF1-Arf1 complexes were compared, the BFA-interacting
regions of the interfacial cleft were virtually identical. Nevertheless, the observation that the
GBF1-M832L mutant was resistant to both BFA and GCA suggested that these compounds
may bind within the same GBF1-Arf1 interfacial region. When GCA was docked into this
pocket, it was found to extend past the BFA-binding region to contact a tripeptide loop that
exists in GBF1 and is lacking in other ArfGEFS, including ARNO, BIG1 and BIG2 (Figure
4c).
The contribution of the GBF1 tripeptide extension to GCA susceptibility was investigated
by mutagenesis. Deletion of residues 845 to 848 or substitution of alanines for all three
residues resulted in resistance to GCA, as indicated by the ability of these mutants to
maintain Golgi morphology in the presence of the compound (Figure 4d). However, as
expected, these mutants remained susceptible to BFA (Figure 4d), as this loop lies outside
the BFA-binding pocket and would not be expected to contribute to BFA susceptibility
(Supplemental Figure 8a). Further mutagenesis of individual residues revealed that
substitution of alanine for arginine 843, glutamine 845 or asparagine 846 resulted in loss of
susceptibility to GCA, while none of these residues were required for BFA susceptibility
(Supplemental Figure 8b). Lysine 844, which protrudes from the opposite side of the GBF1
loop did not affect GCA susceptibility. In summary, these results reveal that GCA
susceptibility is dependent upon resides within a tripeptide found within the GBF1 Sec7
domain.
GCA causes a decrease in GBF1-mediated Arf1 activation
GBF1 facilitates the exchange of GDP for GTP on Arf15,6. To determine whether GCA
affected GBF1-mediated Arf1 activation, cells were treated with this compound or with
BFA and Arf1-GTP was isolated from cellular extracts35. GCA caused a consistent and
statistically significant decrease of 34% in Arf1 activation in vivo (Figure 5). BFA caused a
greater decrease in Arf1-GTP (approximating 75% compared to untreated control) which
was expected given this compound’s more promiscuous effects on ArfGEFs. In order to
directly determine whether the effect of GCA on Arf1 activation was due to inhibition of
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tGBF1 function, cells were transduced with the GCA- and BFA-resistant GBF1-M832L
mutant and Arf1-GTP levels were assessed in cells treated with these compounds. Whereas
GBF1-M832L expression restored Arf1-GTP to approximately 45% of control in BFA-
treated cells, Arf1 activation was increased to 86% of control in GCA-treated cells (Figure
5). Interestingly, expression of GBF1-M832L resulted in increased cellular Arf1-GTP levels
in untreated cells.
In summary, GCA caused a decrease in Arf1 activation which was attenuated in cells
expressing the GCA-resistant mutant. The inability of GBF1-M832L overexpression to
completely restore Arf1-GTP levels in GCA-treated cells to the levels of untreated cells was
likely because GBF1-M832L expression was not observed in all of the cells (Supplemental
Figure 9). BFA caused a much larger decrease in cellular Arf1-GTP and the effect was only
partially reversed by the expression of GBF1-M832L. Both of these observations are
explained by BFA effects on ArfGEFs other than GBF1. Indeed, these data provide a rough
estimate of the relative contribution of GBF1 and other ArfGEFs to cellular Arf1 activation.
These data suggest that in Vero cells growing under tissue culture conditions, GBF1
accounts for approximately 30% of cellular Arf1 activation, BIG1 and BIG2 account for
approximately 45%, and BFA-resistant Arf1GEFS such as ARNO, account for the
remainder.
Inhibition of GBF1 function arrests secretion of soluble and membrane-anchored proteins
Having demonstrated that GCA was a specific inhibitor of GBF1 function, we used this
compound to examine the role of GBF1 in secretory transport. Previous studies with a
dominant-inactive mutant indicated that GBF1 function was required for maturation of ER-
Golgi intermediate vesicles to a transport-competent state4,5. Recent studies with siRNA-
mediated inhibition suggested that GBF1 was required for anterograde transport of
membrane-anchored cargo but was not required for secretion of soluble molecules4.
To assess the role of GBF1 in secretion of membrane-anchored proteins, we examined the
effect of GCA on transport of a GFP-tagged, temperature sensitive VSV-G mutant,
tsVSVG-GFP36. At the non-permissive temperature of 40°C, this protein is retained and
accumulates in the ER. Following a shift to the permissive temperature (32°C), tsVSVG-
GFP transits through the ERGIC to the Golgi and ultimately to the plasma membrane. Cells
were transfected either with tsVSVG-GFP alone or co-transfected with plasmid encoding
GBF1-WT or GBF1-M832L, and the fate of tsVSV-G was followed in GCA-treated cells. In
untreated cells, tsVSVG-GFP was transported from the ER to Golgi within 60 mins and was
located predominantly at the plasma membrane by 4 hrs (Figure 6a). GCA treatment,
however, caused tsVSVG-GFP to be partially retained in a reticular, ER-like distribution
and was also found in diffuse punctate structures (Figure 6b). GBF1-WT overexpression did
not overcome the block in tsVSVG-GFP secretion in GCA-treated cells, whereas co-
transfection with GBF1-M832L restored tsVSVG-GFP transport to the plasma membrane
(Figure 6c). Expression of the GCA-resistant GBF1 loop mutants also restored transport of
(tsVSVG-GFP) to the plasma membrane in the presence of GCA (Supplemental Figure 10).
GCA treatment did not completely block tsVSVG-GFP transport from the ER, as this
protein was also found in peripheral punctate structures after 60 min incubation. These
structures were identified as the ER-Golgi intermediate compartment by their labeling with
anti-ERGIC53, indicating that tsVSVG-GFP was capable of transport from the ER to the
ERGIC in cells lacking GBF1 function. (Figure 6d).
To monitor the secretion of soluble cargo proteins, we expressed GFP bearing a
neuropeptide Y secretion signal (NPY-GFP)37. This protein is secreted from Vero cells with
a half life of approximately 60 minutes, as judged by pulse chase experiments22. Vero cells
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texpressing NPY-GFP demonstrated markedly decreased GFP secretion in the presence of
GCA. If inhibition of NPY-GFP secretion in GCA-treated cells was solely due to the
inhibition of GBF1 function, then expression of the GCA-resistant GBF1-M832L mutant
should restore protein secretion to levels seen with untreated cells. Therefore, the effect of
expressing GBF1-WT or GBF1-M832L on GFP secretion was assessed in GCA-treated
cells. Whereas cells transduced with GBF1-WT failed to transport NPY-GFP to the plasma
membrane in the presence of GCA, the expression of GBF1-M832L restored of NPY-GFP
transport through the Golgi to the plasma membrane (Figure 6e). Together, these findings
reveal that GBF1 function is required for secretion of both soluble and membrane-associated
model proteins.
Inhibition of GBF1 function impairs retrograde toxin transport
We next assessed the role of GBF1 in endocytic and retrograde transport pathways by
tracking the intracellular fate of cholera toxin (Ctx), shiga toxin (Stx), and transferrin (Tfn).
These ligands bind to receptors at the plasma membrane and are transported in retrograde
direction to recycling endosomes. From there, Tfn recycles back to the plasma membrane,
while Stx and Ctx are transported from endosomes to the TGN, eventually reaching the ER
via the Golgi. As described earlier, GCA treatment did not affect the transport of Ctx or Tfn
to perinuclear recycling endosomes nor did it affect the rate of Tfn recycling to the plasma
membrane. These results indicate that GBF1 function is not required for transport through
endocytic transport pathways.
We next examined the effect of GCA on transport of Stx from endosomes to the TGN using
a Stx B subunit that bears overlapping tyrosine sulfation sites (StxB-SS)22. During its
transport through the retrograde transport pathway, this protein is transported from
endosomes to the TGN, where it is sulfated by resident tyrosyl-protein
sulfotransferases38,39. However, treatment with BFA and GCA resulted in marked
attenuation of toxin sulfation. Expression of GBF1-WT failed to rescue the transport of
StxB-SS to the TGN in BFA and GCA-treated cells. Expression of GBF1-M832L only
partially restored toxin sulfation to control levels in BFA-treated cells, presumably because
this compound also inhibits BIG1 and BIG2. However, expression of GBF1-M832L
completely restored toxin sulfation to control levels in GCA-treated cells (Figure 6f). These
results indicate that GBF1 function is required for toxin transport from endosomes to the
TGN. Whether GBF1 functions directly in endosome-to-TGN transport, or indirectly
through its effects on maintaining Golgi structure, is currently unknown.
GCA was identified in a high-throughput screen for its ability to inhibit the effects of shiga
toxin on mammalian cells. The data presented thus far indicate that retrograde toxin
transport was arrested within the endocytic compartment. To determine whether the effects
of GCA on toxin transport were due solely to GBF1 inhibition, we examined the ability of
GBF1-M832L to restore toxin susceptibility to GCA-treated cells. Cells were transduced
with the appropriate GBF1 constructs and treated with GCA. Toxin susceptibility was highly
attenuated in control cells and those transduced with GBF1-WT. In contrast, Stx
susceptibility was fully restored in GCA-treated cells expressing GBF1-M832L, indicating
that the effects of GCA on toxin susceptibility were solely due to GBF1 inhibition (Figure
6g). Together, these results indicate that GBF1 function is not required for transport of
bacterial toxins to recycling endosomes, but this ArfGEF is required for retrograde transport
of Stx from endosomes to the TGN and Golgi.
DISCUSSION
Phenotypic screens aimed at identifying inhibitors of endocytic and secretory transport have
uncovered small molecules that are highly useful probes of intracellular transport. Exo1
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t(3)40 and Exo2 (4)41 were uncovered from an image-based screen for inhibitors of secretory
transport and exhibited Golgi-disruptive effects. Studies with Exo2 revealed that treatment
with this compound ablated the Golgi but maintained TGN integrity and suggested the
existence of an alternative pathway for cholera toxin transport. Exo1 exhibited BFA-like
effects on Arf1 dissociation from Golgi membranes, but unlike BFA, it did not interfere with
ArfGEF activity. A high-throughput screen for inhibitors of dynamin GTPase activity
discovered dynasore (5), a particularly useful probe for studying the dynamics of dynamin-
mediated clathrin coat formation42,43. Similarly, secramine (6) was identified as a novel tool
for dissecting the functions of Cdc42 and possibly other RhoGTPases44. Finally, SecinH3
(7), an inhibitor of the cytoadhesins was recently identified and its use revealed a role for
these BFA-insensitive ArfGEFs in insulin signaling45. Together, these studies underscore
the utility of small molecules as biological probes for dynamic intracellular processes.
Herein we describe the identification and characterization of golgicide A (GCA), a potent,
highly effective, and rapidly reversible inhibitor of GBF1. Mutagenesis and molecular
modeling revealed that GCA binds within the an interfacial cleft formed between Arf1 and
the GBF1 Sec7 domain. Interestingly, BFA binds within this cleft46,47 and substitution of
methionine 832 to leucine results in resistance to BFA 33,32, as well as to GCA. However,
GCA extends beyond the BFA-binding cleft to contact a tripeptide loop present in GBF1 but
lacking from all other known Arf1GEFS, accounting for its selectivity.
Having demonstrated the highly selective nature of GCA activity, we used the compound to
delineate the role of GBF1 in anterograde and retrograde transport through the Golgi. We
found that transport of tsVSVG-GFP was arrested in the ER-Golgi intermediate
compartment, indicating that GBF1 function was not required for exit of cargo from the ER,
but was required for transport past the ERGIC. These results are similar to those found with
expression of a dominant-negative GBF1 and by siRNA-mediated inhibition of GBF148.
Inhibition of GBF1 function with GCA also blocked secretion of GFP bearing a secretion
signal. This finding differs from RNAi-based studies which found relatively mild effects of
GBF1 inhibition on Golgi morphology and which suggested GBF1 was not required for
secretion of soluble cargo4. The relatively milder effects of GBF1 inhibition by RNAi likely
resulted from less than complete inhibition of GBF1 expression, as functional inhibition by
GCA resulted in marked disruption of Golgi morphology and an absolute block in secretion
of soluble and transmembrane proteins.
The role of GBF1 in retrograde transport to the Golgi has not previously been investigated.
We demonstrate that endocytic cargo is transported normally through recycling endosomes
in the presence of GCA, indicating that GBF1 function is not required for these pathways.
However, upon inhibition of GBF1 function, bacterial toxins are trapped in the endocytic
compartment and are unable to reach the dispersed TGN, indicating that GBF1 function is
required to maintain communication between endosomes and the TGN.
In summary, GCA revealed essential roles for GBF1 in maintaining Golgi structure and
enabling anterograde and retrograde traffic through the Golgi and TGN. Given its
specificity, efficacy, and reversibility, GCA will be a unique and powerful tool to further
elucidate the mechanisms underlying assembly and transport within the Golgi.
METHODS
Chemical characterization of GCA
GCA was identified from a commercial compound library available from ChemDiv.
Analysis of the screening DMSO solution by reverse-phase LC-MS revealed the compound
to be present as a 10:1 diastereomeric mixture. The compound was resynthesized using a
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tpublished procedure (Supplementary Methods) which also resulted in a 10:1 diastereomeric
mixture which was determined to be identical to that obtained from the screening library
by 1H NMR and LC-MS. Purification of the major isomer was achieved by recrystallization
from acetonitrile and water. The biological activity of this purified major isomer was
identical to the material obtained from the library DMSO solution. The calculated molecular
weight is 284.3. 1H NMR 600 MHz (CDCl3) δ 8.78 (d, J = 1.5 Hz, 1H), 8.62 (dd, J = 1.2,
3.8 Hz, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.52 (m, 1H), 6.63 (m, 2H), 5.83 (m, 1H), 5.69 (m,
1H), 4.70 (d, J = 2.9 Hz, 1H), 4.10 (d, J = 8.5 Hz, 1H), 3.95 (s, 1H), 3.00 (m, 1H), 2.59 (m,
1H), 1.82 (m, 1H); 13C NMR 150 MHz (CDCl3) δ 147.7, 147.2, 138.7, 135.8, 133.0, 132.2,
131.1, 124.3, 110.4, 110.3, 101.3, 101.2, 101.1, 55.6, 46.2, 45.6, 31.3; MS m/z 285.19 (M +
1).
Radioactive protein synthesis assay
The luciferase-based high-throughput screen to identify inhibitors of Stx trafficking has
previously been described22,49 Confirmation of positive hits from the ChemDiv4 library
screen was assessed by a previously described radioactiveassay22 and is described in
Supplementary Methods.
Immunofluorescence
For all immunofluorescence experiments, cells were fixed in 4% paraformaldehyde in cold
PBS, permeabilized with 0.1% Triton X-100 in PBS, blocked, then probed with primary and
secondary (Alexa Fluor 488 or 594-labeled donkey anti-IgG) antibodies diluted in blocking
buffer (DMEM containing 10% fetal calf serum plus, 1 mg/ml BSA). Cells were rinsed
thoroughly in PBS prior to mounting in SlowFade Gold reagent containing DAPI.
Fluorescence imaging used epifluorescence (Zeiss) microscopy.
Cloning, sequence analysis, site-directed mutagenesis and generation of adenoviral
expression constructs
The hamster GBF1 cDNA (a gift from Paul Melançon, University of Alberta, Edmonton,
AB) was used as template for constructing HA-tagged wild-type and mutant cDNA.
Methods and primer sequences for cloning of canine GBF1 Sec7 domain, mutagenesis of
GBF1, and generation of adenoviral constructs is described in Supplementary Methods.
Arf1-GTP pulldown assay
Was performed with human Arf1 and the VHS and GAT domains of human GGA3, cloned
as purified described in Supplementary Methods. The pulldown assay followed a published
protocol35 with modifications as described in Supplementary Methods.
Molecular Modeling of GBF1-Arf1-GCA complex
The GBF1 homology model was built using Prime 2.0 software from FirstDiscovery suite
(Schrodinger, LLC, Portland, OR) and ARNO coordinates from ARNO-Arf1 complex (PDB
id 1r8q) as a template34. Fully flexible ligand docking was performed with Glide 5.0
(Schrodinger, LLC, Portland, OR). The protein was prepared for grid generation and
subsequent docking using the Protein Preparation Wizard tool from FirstDiscovery suite.
The default settings for grid calculations and docking were used. Images were created with
UCSF Chimera version 1.2540 for Windows50.
Toxin and transferrin internalization
For CtxB and transferrin trafficking experiments, Vero cells grown in chamber slides (2.5 ×
104 cells/chamber) were treated with serum-free medium containing DMSO, GCA, or BFA
at the indicated concentrations and times at 37°C. Following the binding of toxin and
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ttransferrin at 4°C, cells were shifted to 19°C for 1 h to allow for toxin internalization. Cells
were processed for immunofluorescence as described above.
Trafficking of tsVSVG-GFP, NPY-GFP secretion, and StxB-SS-His sulfation assays
Transport of tsVSVG-GFP36, secretion of NPY-GFP22, and sulfation of StxB-SS-His22 were
performed using published protocols with modifications as described in Supplementary
Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Discovery of GCA as a potent and effective inhibitor of Stx susceptibility. (a) Structure of
GCA. (b) Vero cells were pretreated for 30 min at 37°C with varying concentrations of
GCA, followed by incubation with Stx (1 ng/mL) for 4 h at 37°C. % Protein synthesis
indicates the amount of radioactive amino acid incorporation in GCA-treated cells as a
percentage of radioactive amino acid incorporation in cells lacking Stx treatment (control).
Protein synthesis levels and compound-response curves were determined as described in
Methods. (c) Protein synthesis levels for control (squares; no compound) or GCA-treated
(triangles; 10 μM) Vero cells were determined using the radioactive amino acid
incorporation assay as described in (b). % Protein synthesis is expressed as the amount of
radioactive amino acid incorporation in untreated or GCA-treated cells at a given toxin
concentration as a percentage of radioactive amino acid incorporation in cells lacking Stx
treatment. Toxin IC50 values for GCA-treated cells were significantly increased over control
cells (p<0.01; see Methods). For (a) and (b), data points (mean ±SD) represent triplicate data
at the indicated compound or toxin concentrations, respectively, from one representative
experiment. Stx, Shiga toxin; GCA, golgicide A.
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tFigure 2.
GCA disperses medial- and cis-Golgi, inhibits COPI recruitment, and maintains localization
of AP-1 and GGA3 to TGN. (a,b) Vero cells were either left untreated or treated with BFA
(10 μg/mL) or GCA (10 μM) for 1 hr, and the localization of (a) giantin (medial-Golgi), (b)
GM130 (cis-Golgi), and (c) TGN46 (TGN) were determined (see Methods). The distribution
of medial- and cis-Golgi was similar in BFA- and GCA-treated cells, while GCA did not
induce tubulation of the TGN as observed in BFA-treated cells. (d) Vero cells treated for 5
min with BFA (10 μg/mL) or GCA (10 μM) show dispersed COPI staining (arrows) that
does not colocalize with the Golgi (green) as in untreated cells. (e,f) Unlike BFA, GCA
maintains (e) AP-1 and (f) GGA3 association with the TGN after 5 min of treatment (see
arrows). BFA, brefeldin A; blue, nuclei. White scale bars = 20 μm.
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The effects of GCA are similar to expression of inactive GBF1-E794K. (a) Schematic
diagram of the roles of GBF1 and BIG1/BIG2 in Arf1 activation. Arf1 in the inactive (GDP-
bound) form is localized to the cytoplasm. Exchange of GDP for GTP by either BIG1/2 or
GBF1 results in local Arf1 activation, membrane localization, and subsequent recruitment of
vesicle coat proteins such as AP-1 or COPI. (b) Vero cells expressing the GBF1-EK mutant
show dispersal of β-COP, the medial-Golgi (giantin), and the trans-Golgi network (TGN46).
Arrows indicate the effect of GBF1-E794K expression on giantin, βCOP, or TGN46
localization. Blue, nuclei. (c) GBF1-WT is predominantly membrane-associated in GCA-
treated cells and distributed to punctate structures that co-label with anti-ERGIC53. White
scale bars = 20 μm.
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GCA is selective for GBF1 (a) Expression of GBF1-M832L (GBF1-ML) results in
protection from the effects of GCA. Vero cells were transiently transfected with GBF1-ML
and exposed to 100 μM GCA. β-COP, TGN46, and GM130 localization were resistant to
the effects of GCA. Arrows indicate cells expressing GBF1-ML. Blue, nuclei. White scale
bars = 20 μm. (b) Comparison of the amino acid sequence of Sec7 domains reveals
considerable divergence between GBF1 and BIG1/BIG2. Particularly notable was the
presence of three extra residues in the GBF1 sequence (asterisk) (c) The GBF1 Sec7 domain
(residues 693 to 887) was thread on the previously reported ARNO-Arf1-BFA complex.
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modeled tertiary structures are nearly identical, with the exception of an additional loop in
the GBF1 Sec7 domain (asterisk), corresponding to the tripeptide insertion in GBF1
sequence. GCA was docked into the BFA binding pocket, revealing the compound to extend
past the BFA-binding region to make contact with the GBF1 tripeptide loop (middle panel;
light blue). In these images, predicted molecular surfaces are indicated by colored mesh
around the ribbon backbone. The corresponding region of ARNO, BIG1 and BIG2 lacks the
tripeptide (right panel, purple) and does not contact GCA. In these images, GCA is yellow
and Arf1 ribbon diagram is gray. (d) Mutagenesis of the tripeptide, either by deletion of the
three residues, or alteration to three alanine residues results in resistance to GCA but not
BFA. Cells were transiently transfected either with GBF1-WT, GBF1-ML, GBF1-Δ3 (QNV
deleted), or GBF1-AAA (QNV to AAA) then exposed to GCA (10 μM; top panel) or BFA
(10 μg/ml; bottom panel) for 1 hr, and labeled with antibodies against HA and giantin.
White scale bars = 20 μm.
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GCA causes a decrease in GBF1-dependent Arf1 activation. Vero cells transduced with
Arf1-V5 alone or Arf1-V5 plus GBF1-M832L-HA were exposed either to no compound
(Untreated), BFA (10 μg/ml) or GCA (10 μM) for 1 hr. The cells were then lysed and
extracts incubated with immobilized GST-GGA3. Bound proteins were released and
separated by SDS-PAGE. Arf1-V5 was detected by Western blot and band intensity was
determined using ImageJ software. Statistical analysis was performed on duplicate
experiments. (*, statistically significant from untreated sample [P=0.05]; ns, not statistically
significantly different from untreated sample).
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GBF1 inhibition arrests secretion of membrane-anchored and soluble proteins. Trafficking
of tsVSVG-GFP (green) was arrested in GCA-treated cells. Vero cells were co-transfected
with tsVSVG-GFP and either (a) no additional plasmid, (b) wild-type GBF1 (GBF1-WT), or
(c) the GBF1-M832L mutant (GBF1-ML). The cells were incubated at 40°C to trap
tsVSVG-GFP in the ER, followed by treatment with either (a) no compound or (b,c) GCA
(10 μM) prior to shifting the cells to 32°C. At various times (t = 0, 1, and 4 h) following the
temperature shift, cells were fixed and labeled with anti-HA antibody (GBF1 proteins; red).
Expression of the GBF1-ML mutant restored tsVSVG-GFP transit to the plasma membrane
(arrow). (d) tsVSVG-GFP co-localizes with ERGIC53 in GCA-treated cells. Vero cells
transfected with tsVSVG-GFP were incubated at 40°C before a shift to 32°C for 4 h in the
presence of GCA (10 μM). The cells were fixed and labeled with an anti-ERGIC53 antibody
(red). Inset shows magnification of boxed area and co-localization of VSVG with the
ERGIC (yellow). Blue, nuclei. White scale bars = 20 μm. (e) GCA inhibits secretion of
soluble cargo. Cells were transduced either with adenovirus expressing NPY-GFP alone or
co-transduced with NPY-GFP plus adenovirus expressing GBF1-WT or GBF1-ML. The
cells were either left untreated or were exposed to GCA (10 μM) for 1 h. At various times,
the media was removed and GFP concentration assessed by ELISA (see Supplementary
Methods). GCA treatment decreases NPY-GFP secretion in untransduced cells (dotted),
while overexpression of GBF1-ML (blue), but not GBF1-WT (red), restores NPY-GFP
secretion to levels in untransduced, untreated cells (black). (f) Sulfation of a StxB construct
with a tandem of sulfation sites (StxB-SS) was used to assess trafficking from endosomes to
the TGN. Control Vero cells, or those transduced with GBF1-WT or GBF1-ML were
preincubated with no compound, BFA (10 μg/ml) or GCA (10 μM), then StxB-SS was
added for 3 hrs in the presence of [35S]O4 as described in Supplementary Methods. StxB-SS
was recovered from cell lysates and subjected to SDS-PAGE and autoradiography to detect
radiolabeled toxin. (g) Inhibition of shiga toxicity by GCA is completely reversed in cells
expressing GBF1-ML. Cells were either left untransduced or transduced with adenovirus
expressing GBF1-WT or GBF1-ML and were exposed either to GCA (solid line) or no
compound (dotted line) prior to treatment with increasing concentrations of Stx. After 4 h
incubation, protein synthesis was assessed, as described in Supplementary Methods. GBF1-
ML expression restores Stx susceptibility in GCA-treated cells.
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